• Company Type For Profit
  • Contact Email info@ccam-bio.com
  • Phone Number 972 4 681 8829

cCAM Biotherapeutics is a pre-clinical stage company developing immunotherapies for cancer. cCAM's lead agent, CM-10, is an immunomodulatory antibody that harnesses the patient's immune system to attack tumors. CM-10 binds CEACAM1, a protein used by cancer cells to suppress the immune system. CM-10 abrogates this effect, leading to a

cancer specific immune response in patients.

Lists Featuring This Company

Acquired Therapeutics Companies
818 Number of Organizations â€¢ $55.9B Total Funding Amount â€¢ 2,768 Number of Investors
Pontifax Portfolio Companies
67 Number of Organizations â€¢ $8.4B Total Funding Amount â€¢ 534 Number of Investors
Closed Middle East Companies
4,161 Number of Organizations â€¢ $5.5B Total Funding Amount â€¢ 1,732 Number of Investors
OrbiMed Portfolio Companies
410 Number of Organizations â€¢ $116.7B Total Funding Amount â€¢ 4,329 Number of Investors
cCAM Biotherapeutics was acquired by Merck for $95M on Jul 28, 2015. This deal was done in Cash.

Frequently Asked Questions

Where is cCAM Biotherapeutics's headquarters? cCAM Biotherapeutics is located in Qiryat Shmona, HaZafon, Israel.Who invested in cCAM Biotherapeutics? cCAM Biotherapeutics has 3 investors including Arkin Holdings and OrbiMed.When was the last funding round for cCAM Biotherapeutics? cCAM Biotherapeutics closed its last funding round on Sep 15, 2012 from a Series A round.Who are cCAM Biotherapeutics's competitors? Alternatives and possible competitors to cCAM Biotherapeutics may include Adze Biotechnology and Vaxil BioTherapeutics.